Abstract
Potassium channels form highly K+ ion-selective pores in the plasma membrane of excitable cells. Voltagegated potassium (Kv) channels open in response to membrane depolarization to allow rapid diffusion of K+ ions out of the cell, thus repolarizing the cell to restore a negative resting membrane potential. Inherited mutations in Kv channel genes produce abnormal cellular repolarization and cause diseases of excitable tissues. Small molecule interactions with Kv channels can cause similar pathologies. During the last decade of research into Kv channels and associated diseases - termed ‘channelopathies’ - we have begun to understand Kv channel function and dysfunction at the molecular level. In this review, the molecular mechanisms of Kv channelopathies are discussed, with particular emphasis on the overlap between inherited and acquired disease, and the drive towards novel channel-targeted therapies.
Keywords: Arrhythmia, hERG, IKr, IKs, KCNE, KCNQ1, Kv1.5, MinK, MiRP1
Current Pharmaceutical Design
Title: Molecular Mechanisms of Cardiac Voltage-Gated Potassium Channelopathies
Volume: 12 Issue: 28
Author(s): Geoffrey W. Abbott
Affiliation:
Keywords: Arrhythmia, hERG, IKr, IKs, KCNE, KCNQ1, Kv1.5, MinK, MiRP1
Abstract: Potassium channels form highly K+ ion-selective pores in the plasma membrane of excitable cells. Voltagegated potassium (Kv) channels open in response to membrane depolarization to allow rapid diffusion of K+ ions out of the cell, thus repolarizing the cell to restore a negative resting membrane potential. Inherited mutations in Kv channel genes produce abnormal cellular repolarization and cause diseases of excitable tissues. Small molecule interactions with Kv channels can cause similar pathologies. During the last decade of research into Kv channels and associated diseases - termed ‘channelopathies’ - we have begun to understand Kv channel function and dysfunction at the molecular level. In this review, the molecular mechanisms of Kv channelopathies are discussed, with particular emphasis on the overlap between inherited and acquired disease, and the drive towards novel channel-targeted therapies.
Export Options
About this article
Cite this article as:
Abbott W. Geoffrey, Molecular Mechanisms of Cardiac Voltage-Gated Potassium Channelopathies, Current Pharmaceutical Design 2006; 12 (28) . https://dx.doi.org/10.2174/138161206778522065
DOI https://dx.doi.org/10.2174/138161206778522065 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Static Magnetic Fields on Blood Pressure in Animals and Humans
Current Hypertension Reviews Schiff Bases of Benzothiazol-2-ylamine and Thiazolo[5,4-b] pyridin-2-ylamine as Anticonvulsants: Synthesis, Characterization and Toxicity Profiling*
Central Nervous System Agents in Medicinal Chemistry Functional Chemical Groups that May Likely Become a Source for the Synthesis of Novel Central Nervous System (CNS) Acting Drugs
Central Nervous System Agents in Medicinal Chemistry TRP Channels as Novel Targets for Endogenous Ligands: Focus on Endocannabinoids and Nociceptive Signalling
Current Neuropharmacology An Integrated Drug Development Approach Applying Topological Descriptors
Current Computer-Aided Drug Design Recent Progress in Syntheses and Biological Activities of Kainic Acid and its Derivatives
Current Organic Chemistry Cardiovascular Complications in Patients with Klinefelter’s Syndrome
Current Pharmaceutical Design The Pathophysiological Basis of Carotid Baroreceptor Stimulation for the Treatment of Resistant Hypertension
Current Vascular Pharmacology Organotypic Cultures as Tools for Testing Neuroactive Drugs – Link Between In-Vitro and In-Vivo Experiments
Current Medicinal Chemistry Role of SCN2A c.56G/A Gene Polymorphism in Egyptian Children with Genetic Epilepsy with Febrile Seizure Plus
CNS & Neurological Disorders - Drug Targets GABA System as a Target for New Drugs
Current Medicinal Chemistry Port-a-Patch and Patchliner: High Fidelity Electrophysiology for Secondary Screening and Safety Pharmacology
Combinatorial Chemistry & High Throughput Screening synthesis and Structure-Activity Relationships of 2,3-Benzodiazepines as AMPA Receptor Antagonists
Mini-Reviews in Medicinal Chemistry Butyrylcholinesterase K and Apolipoprotein ε4 Affect Cortical Thickness and Neuropsychiatric Symptoms in Alzheimer’s Disease
Current Alzheimer Research “Epileptic Encephalopathy” of Infancy and Childhood: Electro-Clinical Pictures and Recent Understandings
Current Neuropharmacology Presynaptic NR2B-Containing NMDA Autoreceptors Mediate Glutamatergic Synaptic Transmission in the Rat Visual Cortex
Current Neurovascular Research Parkinson Disease Genetics: A "Continuum" from Mendelian to Multifactorial Inheritance
Current Molecular Medicine UGT1A1 Mediated Drug Interactions and its Clinical Relevance
Current Drug Metabolism Current Understanding of Central Nervous System Drainage Systems: Implications in the Context of Neurodegenerative Diseases
Current Neuropharmacology The Potential of Caffeine for Functional Modification from Cortical Synapses to Neuron Networks in the Brain
Current Neuropharmacology